Metrion, LifeArc Extend Collaboration to Support LifeArc's Neuroscience Drug Discovery Programme
News Aug 01, 2017
Metrion Biosciences Limited (Metrion), the specialist ion channel CRO and drug discovery company, and LifeArc, the UK medical research charity previously known as MRC Technology, newly announced an extension of their existing partnership, to support LifeArc’s neuroscience drug discovery programme.
Under the terms of the agreement Metrion will provide validated ion channel and electrophysiology-based assays and safety profiling services, and LifeArc will conduct medicinal chemistry aimed at identifying novel modulators of an undisclosed CNS ion channel target. In addition, Metrion will contribute translational research expertise to evaluate the activity of LifeArc compounds in human neuronal networks.
Metrion will provide translational assay support by applying its extensive background knowledge in ion channel research, microelectrode array (MEA) technology, and access to its CiPA-compliant cardiac safety assays.
Dr Andrew Southan, Chief Operating Officer, Metrion Biosciences, said: “The Metrion team has a long history of developing, validating, and providing specialist ion channel assays to optimise and select development candidate molecules. We believe combining this with translational neuroscience and microelectrode array capability, as we are in this promising project with LifeArc, may be particularly successful in CNS research.”
Justin Bryans, Executive Director, Drug Discovery, LifeArc, commented: “LifeArc is committed to working with cutting edge organisations such as Metrion, capitalising on our combined expertise and capabilities to advance programmes addressing human health. Our previous experience in working with the team at Metrion has been excellent, and we look forward to continuing the relationship.”
Forty to 60 percent of all people treated for substance use disorders relapse, presenting a major challenge to treatment success. New research shows that erasing memories that associate environmental cues with drug use significantly reduces drug seeking behaviors in rats, opening a potential avenue for developing more effective therapies to prevent relapse.